Improved Survival with Bevacizumab in Advanced Cervical Cancer | Zendy

Krishnansu S. Tewari | Zendy; Michael W. Sill | Zendy; Harry J. Long | Zendy; Richard T. Penson | Zendy; Helen Q. Huang | Zendy; Lois M. Ramondetta | Zendy; Lisa M. Landrum | Zendy; Ana Oaknin | Zendy; Thomas Reid | Zendy; Mario M. Leitao | Zendy; Helen E. Michael | Zendy; Bradley J. Monk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Author(s) -

Krishnansu S. Tewari,

Michael W. Sill,

Harry J. Long,

Richard T. Penson,

Helen Q. Huang,

Lois M. Ramondetta,

Lisa M. Landrum,

Ana Oaknin,

Thomas Reid,

Mario M. Leitao,

Helen E. Michael,

Bradley J. Monk

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1309748

Subject(s) - bevacizumab , medicine , topotecan , cervical cancer , paclitaxel , chemotherapy , cisplatin , oncology , hazard ratio , urology , surgery , cancer , confidence interval

Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research